{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:51:03Z","timestamp":1761630663274},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2013,10,1]]},"DOI":"10.2174\/15680096113139990080","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T09:14:28Z","timestamp":1381914868000},"page":"879-894","source":"Crossref","is-referenced-by-count":11,"title":["Ipilimumab and Vemurafenib: Two Different Routes for Targeting Melanoma"],"prefix":"10.2174","volume":"13","author":[{"given":"Ana","family":"Burgeiro","sequence":"first","affiliation":[]},{"given":"Faustino","family":"Mollinedo","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Oliveira","sequence":"additional","affiliation":[]}],"member":"965","container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/115995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T08:38:42Z","timestamp":1448267922000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1568-0096&volume=13&issue=8&spage=879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":0,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,10,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/15680096113139990080","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10,1]]}}}